anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
After cardiopulmonary bypass, patients will receive protamine at dose 0.01 mg/unit of heparin given with target activated clotting time (ACT) within 10% of baseline value. After protamine administration the ACT, complete blood count (CBC), prothrombin time (PT)/ international normalized ratio (INR), activated partial thromboplastin time (APTT), and fibrinogen, will be collected via preexisting arterial access. If ACT \>10% baseline additional protamine will be given at the anesthesiologists discretion. Evaluation and determination of excessive microvascular bleeding in the surgical field will occur 10 minutes after return of ACT to within 10% of baseline. Patients with clinical evidence of excessive microvascular bleeding in the surgical field as determined by the surgical team, along with a PT \>16.6 sec/ INR \>1.6 sec will receive fresh frozen plasma as this is standard therapy per our institutional algorithm at a dose of 10-15 mL/kg rounded up to the nearest unit.
The purpose of this research is to study the dissemination and implementation of MOVE!. MOVE! is a national weight management program for veterans that has moved form pilot to full dissemination. Overweight and obesity are rapidly rising in the United States and interventions to combat this epidemic are desperately needed. Within the VA population, approximately 70% of veterans are overweight and or obese. Participants will be male and female Veterans, aged 21 and over receiving health services at one of the 10 study sites, who qualify for the MOVE! program. We are recruiting a minimum of 800 -1000 Veterans to complete a baseline survey at the 10 VA sites participating in the study. Participants at the 10 VA sites are recruited during a primary care visit by primary care provider, they will not be chosen based on the presence or absence of any disease, thus health status will vary. The primary outcome measures will be participation after enrollment into MOVE! and participant weight loss.
Eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), mainly obtained from fish, have been implicated in fetal development. Because few studies have examined maternal and umbilical cord blood fatty acid levels and infant body size in Japan with a fish-eating culture, we examined differences in plasma fatty acid levels in pregnant women and infant size at birth. This study is a large birth cohort study of 1476 pairs of Japanese pregnant women and their infants. Maternal blood DHA levels and infant birth weight showed a positive relationship. However, analysis adjusted for gestational age did not reveal correlations. Negative relationships were found between cord blood DHA levels and infant body size, and between the difference in mother-to-child DHA levels and infant body size. Thus, the smaller the birth size, the higher the differences in umbilical cord blood DHA levels and mother-to-child DHA levels when considering gestational age.
In the post-stroke group and in the control group, SMWT (Six Minute Walk Test) and SCT( Stair Climb Test) were preceded by a 10-minute rest in sitting position. The time of test performance, the walked distance and steps made as well as the mean and maximum gait velocity and the calories burned were assessed using the above-mentioned Samsung Health application . ECG results were assessed with the use of ECG M-Trace Base II application described above. In addition, cardiological parameters such as: systolic blood pressure (SBP) and diastolic blood pressure (DBP), heart rate (HR) and arterial blood saturation were assessed. The measurements were performed at rest and directly after SCMT and SCT. Additionally, after the tests, the level of dyspnoea and fatigue was assessed according to the modified Borg scale (score 0-10).
The purpose of this trial is to determine if a home blood pressure self-management (HBPS) program, including home monitoring and medication adjustments, is practical to use in recent stroke survivors and whether or not it is associated with lowering blood pressure after 3 months. Data from this trial may be used to do more research and may be used by doctors when seeing patients.This research is being done because high blood pressure, also called hypertension, is the leading risk factor for stroke. Lowering blood pressure (BP) has been shown to lower the risk of future strokes. The majority of stroke survivors continue to have uncontrolled BP. Currently, blood pressure (BP) is most often measured in the doctor's office. However, those single BP measurements are not the best picture of blood pressure over time and can be influenced by the stress of being in a doctor's office, known as the "white coat effect". This is why measuring BP at home may paint a more accurate picture of a patient's true long-term BP. Home blood pressure monitoring (HBPM) is recommended in the recently updated national hypertension guidelines. Home BP monitoring plus guided BP medication self-adjustments is associated with lower BP in patients with high blood pressure. The investigators believe that a HBPS program, including medication self-adjustment and home monitoring, may help to reduce blood pressure in patients with hypertension within 3 months.
A method of manufacturing a stable multiple active veterinary formulation comprising the steps of: a) Dissolving a first active in a solvent b) Sorbing the solvent containing active composition on to a sorbing medium; and c) Dispersing the sorbing medium loaded with the solvent composition in a liquid, wherein the liquid contains at least one further active dissolved or suspended therein. The first active may be a lipophilic active selected from the group including the avermectins and the milbemycins. The liquid may be an aqueous vehicle and the solvent may be selected form oils and organic solvents. The at least one further active may be selected from the group including vitamins, minerals, anthelmintics or antigens. The sorbing medium may be selected from magnesium aluminmetasilicate, cellulose, microcrystalline cellulose, distomaceous earth, montmorillonite, betonite, titanium dioxide, amorphous silicon dioxide, colloidal silicon dioxide (Aerosil), calcium carbonate, talc (SiO2 + MgO), attapulgite (silicon, aluminium and iron oxides clay), kaolin (aluminium silicate) preferable Aerosil, more preferably Aerosil R972. The stable multiple active veterinary formulation produced as a result of the above method is also described. The disclosed formulation is useful in the treatment of a non-human animal.
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in the clinical trials of another drug and may not reflect the rates observed in practice. 

Migraine Headache: Table 1 lists adverse reactions that occurred in 2 U.S. placebo-controlled clinical trials in patients with migraines (Studies 2 and 3) following either a single 6-mg dose of Sumatriptan Injection or placebo. Only reactions that occurred at a frequency of 2% or more in groups treated with Sumatriptan Injection 6 mg and that occurred at a frequency greater than the placebo group are included in Table 1.

The incidence of adverse reactions in controlled clinical trials was not affected by gender or age of the patients. There were insufficient data to assess the impact of race on the incidence of adverse reactions. 

Cluster Headache: In the controlled clinical trials assessing the efficacy of Sumatriptan Injection as a treatment for cluster headache (Studies 4 and 5), no new significant adverse reactions were detected that had not already been identified in trials of Sumatriptan Injection in patients with migraine. Overall, the frequency of adverse reactions reported in the trials of cluster headache was generally lower than in the migraine trials. Exceptions include reports of paresthesia (5% Sumatriptan Injection, 0% placebo), nausea and vomiting (4% Sumatriptan Injection, 0% placebo), and bronchospasm (1% Sumatriptan Injection, 0% placebo).
PURPOSE:To obtain a vasodilator containing wortmannin as an active ingredient and useful as treating agent of hypertension and ischemic heart disease. CONSTITUTION:The objective vasodilator containing wortmannin expressed by the formula as an active ingredient and obtained by properly blending wortmannin further with vehicle for preparation, lubricant, binder, disintegrator, suspension, isotonic agent, emulsion, absorption accelerator, carrier, etc., ordinarily employed, and formulating the blend according to ordinary method. The objective vasodilator can be prepared in the form of tablet, pill, inhalant, granule, capsule, suppository, injection, dropping injection, etc. The daily dosage is 0.01-2mg/kg/adult. The agent is effective on hypertension, occlusive arteriosclerosis, ischemic heart disease, transient ischemic shock, cerebral thrombosis, cerebral embolism, etc. The wortmannin is a metabolite of microorganism and has also antiphlogistic action.
After a baseline blood sample is acquired, participants will consume 100 grams of glucose within 5 minutes. Two additional lancet punctures will be performed after the glucose ingestion, one at 30 minutes post-ingestion, and one at 60 minutes post-ingestion.
A pharmaceutical composition for release regulation comprises a drug layer, a coating layer and polyethylene oxide. The coating layer wraps the outside of the drug layer. The coating layer containing the drug layer is mixed with polyethylene oxide to form the pharmaceutical composition. The polyethylene oxide is characterized in having an average molecular weight more than 2 million Da. The coating layer comprises at least one hydrophilic polymer, a hydrophobic polymer or a composition having a hydrophilic polymer and a hydrophobic polymer. The coating layer of the present invention can form a well coated powder or granule, thereby providing a stably controlled release pharmaceutical composition.
Patients receive full access to INSPIRE website for 6 months, which offers an individually tailored greeting home page with links to information on each of the target areas identified as being elevated on baseline assessment and how to manage the complications; a bulletin board with input from other survivors that is solicited, edited, and posted weekly; resource pages; and an opportunity to send secure messages with questions or comments. Patients also undergo 4-8 phone-based PST sessions with a behavioral health specialist.
The invention relates to a novel method to produce small RNAs targeting pathogenicity factors, essential genes and /or antimicrobial resistance genes of animal pathogens. This method also includes the production of small RNAs directed against host susceptibility factors, whose silencing, inactivation, or deletion, is known to enhance resistance towards the targeted pathogen(s). More specifically, the invention involves the expression of exogenous RNA interference (RNAi) precursor(s) in  Chlorella  cells, which in turn express and release Extracellular Vesicle (EV)-embedded antimicrobial small RNAs. Importantly,  Chlorella  EVs protect antimicrobial small RNAs from ribonuclease-mediated digestion. They are also rapidly and efficiently internalized by human alveolar epithelial cells, highlighting their potential for delivering antimicrobial small RNAs in these cells, and for controlling respiratory infections. The invention can thus be used for prophylactic or therapeutic treatments, to reduce various infectious diseases in animals, including humans. Furthermore, because the integrity and functionality of  Chlorella  EVs remain unaltered when produced in photobioreactors, and when stored frozen, this novel method has the potential to be further exploited for the industrialization of EV-based anti-infective products.
The invention discloses application of a mycelium extract of a strain culture of marine fungus umbelopsis sp. in preparation of antibacterial drugs. The mycelium extract of the strain culture of marine fungus umbelopsis sp. is prepared according to the following steps: 1) selecting a mycelium of marine fungus umbelopsis sp. QZ042 with the preservation number of CGMCC No. 8101, inoculating the mycelium on a PDA solid medium, and carrying out slant culture; 2) inoculating the fungus subjected to slant culture on a PD liquid medium, and carrying out shaking culture for 5-7 days or static culture for 15-30 days at the temperature of 25-32 DEG C, so as to obtain a fermented culture; 3) filtering the fermented culture, so as to separate the mycelium from the fermentation liquor; 4) taking the mycelium, extracting with a mixed solvent, and concentrating the extract liquid, so as to obtain the mycelium extract. The applicant discovers that the mycelium extract has relatively good antibacterial activity for bacteria, such as, escherichia coli, bacillus cereus, arthrobacter nicotianae, klebsiella peneumoniae and vibrio parahaemolyticus.
Peripheral venous catheterization is the most commonly performed invasive procedure in healthcare. Care practices and the use of technologies may influence the results of the use peripheral intravenous catheters (PIC), contributing to the reduction of complications and adverse events. Phlebitis is characterized as one of the most serious complication related to the use of PIC and this study has as hypothesis to analyze if the occurrence of phlebitis associated with PIC is influenced by the use of sterile dressing. Objectives: To verify the effect of using sterile dressing and sterile adhesive tape compared to non-sterile adhesive tape in PIC on the occurrence of phlebitis in adult patients attended at a hospital from the Western Brazilian Amazon. Methods: Pragmatic, randomized, controlled and single-blinded clinical study conducted in Rio Branco, Acre. The sample was calculated in 330 patients, aged 18 years or older and who met the inclusion criteria. Data collection took place between June 2018 and September 2019, after approval of ethical merit. To identify the type of sterile transparent dressing to be studied, was carried out an implementation study with a final sample of 71 patients, focusing analysis from the perspective of the patient, professional and clinics. The patients of the clinical study were randomly allocated to one of the study groups: Experimental group (sterile transparent dressing) or Standard Group (non-sterile adhesive tape). Phlebitis was diagnosed by the bedside nurse, according to presence and severity. If present, the nurse removed the CIP and an external evaluator was called to perform a diagnose of phlebitis with blindness regarding the intervention. Variables related to patient characterization, intravenous therapy, peripheral venipuncture, reasons for withdrawal and length of PIC stay, reasons for removal and length of coverage, and associated complications were investigated. For the statistical analysis, Chi-square, Fisher's Exact, student t test, and Mann-Whitney U tests were used. The multiple analysis was performed using the logistic regression model to estimate the Relative Risk (RR) and the Kaplan-Meier model, Cox regression, for survival analysis. RR calculation for 95% Confidence Interval (IC) was applied to estimate the degree of association between variables. In all tests, the significance level of 5% was considered.
For the first 4 weeks, participants were taught about the symptoms and associated behavioral changes of dementia and the possible effects on the caregivers, the physical, social and psychological consequences of stress, event scheduling and communication skills. After psychoeducation, eight biweekly phone sessions of general support but not behavioral activation.
BACKGROUND AND AIMS: Exercise training is recommended for all patients with metabolic dysfunction-associated steatotic liver disease and may reverse liver fibrosis. Whether exercise training improves liver fibrosis without body weight loss remains controversial. We further investigated this relationship using serum biomarkers of liver fibroinflammation in a post hoc analysis of an exercise trial where patients did not lose significant body weight.
METHODS: In the NASHFit trial, patients with metabolic dysfunction-associated steatohepatitis were randomized to receive either moderate-intensity aerobic exercise training or standard clinical care for 20 weeks. Mediterranean-informed dietary counselling was provided to each group. Change in serum biomarkers was measured and compared between the two groups.
RESULTS: Exercise training led to improvement in serum biomarkers of liver fibroinflammation, including (1) ≥17 IU/L reduction in alanine aminotransferase (ALT) in 53% of individuals in the exercise training group compared to 13% in the standard clinical care group (p < 0.001; mean reduction 24% vs. 10% respectively) and (2) improvement in CK18 (-61 vs. +71 ng/mL, p = 0.040). ALT improvement ≥17 IU/L was correlated with ≥30% relative reduction in magnetic resonance imaging-measured liver fat and PNPLA3 genotype.
CONCLUSION: Exercise training improves multiple serum biomarkers of liver fibroinflammation at clinically significant thresholds of response without body weight loss. This study provides further evidence that exercise training should be viewed as a weight-neutral intervention for which response to intervention can be readily monitored with widely available non-invasive biomarkers that can be applied at the population level.
Sarcopenia, which refers to age-related muscle loss, presents a significant challenge for the aging population. Age-related changes that contribute to sarcopenia include cellular senescence, decreased muscle stem cell number and regenerative capacity, impaired autophagy, and mitochondrial dysfunction. Metformin, an anti-diabetic agent, activates AMP-activated protein kinase (AMPK) and affects various cellular processes in addition to reducing hepatic gluconeogenesis, lowering blood glucose levels, and improving insulin resistance. However, its effect on skeletal muscle cells remains unclear. This study aimed to investigate the effects of metformin on age-related muscle loss using a late passage C2C12 cell model. The results demonstrated that metformin alleviated hallmarks of cellular senescence, including SA-β-gal activity and p21 overexpression. Moreover, treatment with pharmacological concentrations of metformin restored the reduced differentiation capacity in late passage cells, evident through increased myotube formation ability and enhanced expression of myogenic differentiation markers such as MyoD, MyoG, and MHC. These effects of metformin were attributed to enhanced autophagic activity, normalization of mitochondrial membrane potential, and improved mitochondrial respiratory capacity. These results suggest that pharmacological concentrations of metformin alleviate the hallmarks of cellular senescence, restore differentiation capacity, and improve autophagic flux and mitochondrial function. These findings support the potential use of metformin for the treatment of sarcopenia.
The protocol compares arterial pressures produced by an automated self-adjusting load-distributing band device (AutoPulse™ 100, Zoll®) with those of manual cardiopulmonary resuscitation in refractory out-of-hospital cardiac arrest. Each patient will receive first manual compressions and then automated resuscitation.

Patients presenting with cardiac arrest are treated following standard advanced life support guidelines. They are intubated and ventilated, received epinephrine and defibrillation if appropriate. Manuel chest compressions are continued. An arterial catheter is placed to monitor hemodynamics continuously as we usually do in this case. Patients are included at this stage. Three blood pressure values (every 1 minutes) are recorded. Then, the automated band device is started up without any pause, following our procedure for refractory cardiac arrest. Three blood pressure values are recorded again, during automated cardiopulmonary resuscitation.
PROBLEM TO BE SOLVED: To obtain the subject therapeutic agent containing gluconic acid or its salt as an active component, having a suppressive activity against the lowering of magnesium absorption attributable to an excess intake of phosphorus or calcium and useful for prophylaxis, treatment, etc., of hypertension, ischemic heart disease, etc. SOLUTION: This therapeutic agent contains gluconic acid or its salt, preferably calcium gluconate as an active component. Further, as the gluconic acid, e.g. any compound selected from D-isomer, L-isomer and DL-racemate can be used. Optionally, a nutritional component such as a casein enzyme- decomposed product or vitamin D, a vehicle or an extender such as lactose, a starch or a dextrin, etc., is compounded. In the case where calcium gluconate is used, a daily dose is preferably 500mg to 1g in terms of calcium.
* Background: In recent years Left Ventricular Assist Devices (LVADs) have become the devices of choice to treat patients with advanced heart failure. Proper evaluation of the cardiovascular function under LVAD support is of key importance especially for the preservation of the assisted cardiac function or for the evaluation of an eventual cardiac recovery. Cardiac echocardiography, electrocardiography and catheterization, as well as exercise testing are the standard clinical methods for the evaluation of the cardiovascular function during LVAD support. All these methods require however time-consuming procedures, and are therefore unacceptably cumbersome for frequent monitoring. On the other hand, a frequent and effective noninvasive evaluation of the cardiac status provided by the LVAD itself would have a remarkable impact on LVAD patients and their therapy. Previously developed methods to assess the cardiovascular status from data available from the LVAD (see references given) will be now investigated in a prospective clinical study.
* Purpose: The main purpose of this study is evaluate the sensitivity/specificity of LVAD based diagnostics when compared to standard clinical diagnostic procedures both at rest and during exercise. Secondarily, the physical activity of patients will be evaluated following LVAD implantation.
* Methods: Seventy-five heart failure patients who had or are about to have a LVAD implanted will be enrolled in this study. In these patients, the LVAD data (motor current and speed) will be recorded concurrently to the routine clinical examinations and during daily life. The routine clinical examinations typically consist of a subset of the following procedures: cardiac ultrasound, cardiac catheterization, 24h ECG measurement, exercise tests (6-minute walk test and spiroergometry). Parameters from the LVAD data that reflect contractile and relaxation properties as well as and aortic valve opening will be compared to echocardiography. Parameters from the LVAD data that reflect cardiac rhythms will be compared to ECG measurements. Both cardiac hemodynamics and rhythms during exercise tests will be assessed using the developed methods based on LVAD data. Finally, wristwatch accelerometers will be used for a quantification and evaluation of patient daily life activity. This measurements will be compared to 6-minute walk test and spiroergometry data as well as with the diagnostics methods based on the LVAD data.
The individuals in the control group will be asked to brush their teeth (2x per day) at home throughout the 4 weeks of study period. They will be asked not to use the supplementary oral hygiene products including mouth rinse, dental floss and chewing gum.